Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice

Vascular Pharmacology

Volumn 74, Issue , 2015, Pages 103-113

  Fraga Silva, Rodrigo A ^a   Montecucco, Fabrizio ^b,c   Costa Fraga, Fabiana P ^a   Nencioni, Alessio ^c   Caffa, Irene ^c   Bragina, Maiia E ^a   Mach, François ^b   Raizada, Mohan K ^d   Santos, Robson A S ^e   da Silva, Rafaela F ^e   Stergiopulos, Nikolaos ^a  

^a EPFL   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Angiotensin; Angiotensin converting enzyme 2; Atherosclerosis; Diminazene; Inflammation; Plaque stability; Plaque vulnerable

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; APOLIPOPROTEIN E; CHEMOKINE; COLLAGEN; CYTOKINE; DIMINAZENE; GAMMA INTERFERON; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; AORTA SINUS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ATHEROSCLEROSIS; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHEAR STRESS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; AORTA; ATHEROSCLEROSIS; C57BL MOUSE; CAROTID ARTERY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PLAQUE, ATHEROSCLEROTIC;

ANGIOTENSIN II; ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CAROTID ARTERIES; COLLAGEN; DIMINAZENE; DISEASE MODELS, ANIMAL; INTERCELLULAR ADHESION MOLECULE-1; MACROPHAGES; MICE; MICE, INBRED C57BL; PEPTIDYL-DIPEPTIDASE A; PLAQUE, ATHEROSCLEROTIC; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84947617662     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.08.014     Document Type: Article

References (53)

1. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995, 92(3):657-671.
2. Schroeder A.P., Falk E. Vulnerable and dangerous coronary plaques. Atherosclerosis 1995, 118 Suppl.:S141-S149.
3. Gambillara V., Chambaz C., Montorzi G., Roy S., Stergiopulos N., Silacci P. Plaque-prone hemodynamics impair endothelial function in pig carotid arteries. Am. J. Physiol. Heart Circ. Physiol. 2006, 290(6):H2320-H2328.
4. Gambillara V., Montorzi G., Haziza-Pigeon C., Stergiopulos N., Silacci P. Arterial wall response to ex vivo exposure to oscillatory shear stress. J. Vasc. Res. 2005, 42(6):535-544.
5. Cheng C., Tempel D., van Haperen R., van der Baan A., Grosveld F., Daemen M.J., Krams R., de Crom R. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 2006, 113(23):2744-2753.
6. Keidar S., Attias J., Heinrich R., Coleman R., Aviram M. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis. Atherosclerosis 1999, 146(2):249-257.
7. Weiss D., Kools J.J., Taylor W.R. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001, 103(3):448-454.
8. da Silva A.R., Fraga-Silva R.A., Stergiopulos N., Montecucco F., Mach F. Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis. Eur. J. Clin. Invest. 2015, 45(3):274-287.
9. Keidar S., Heinrich R., Kaplan M., Hayek T., Aviram M. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler. Thromb. Vasc. Biol. 2001, 21(9):1464-1469.
10. Nickenig G., Harrison D.G. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 2002, 105(3):393-396.
11. Victorino G.P., Newton C.R., Curran B. Effect of angiotensin II on microvascular permeability. J. Surg. Res. 2002, 104(2):77-81.
12. Ni W., Kitamoto S., Ishibashi M., Usui M., Inoue S., Hiasa K., Zhao Q., Nishida K., Takeshita A., Egashira K. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24(3):534-539.
13. Guo R.W., Yang L.X., Wang H., Liu B., Wang L. Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells. Regul. Pept. 2008, 147(1-3):37-44.
14. Wang Y., Tikellis C., Thomas M.C., Golledge J. Angiotensin converting enzyme 2 and atherosclerosis. Atherosclerosis 2013, 226(1):3-8.
15. Jiang F., Yang J., Zhang Y., Dong M., Wang S., Zhang Q., Liu F.F., Zhang K., Zhang C. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat. Rev. Cardiol. 2014, 11(7):413-426.
16. Fraga-Silva R.A., Da Silva D.G., Montecucco F., Mach F., Stergiopulos N., da Silva R.F., Santos R.A. The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. Thromb. Haemost. 2012, 108(6):1089-1096.
17. Tesanovic S., Vinh A., Gaspari T.A., Casley D., Widdop R.E. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30(8):1606-1613.
18. Fraga-Silva R.A., Savergnini S.Q., Montecucco F., Nencioni A., Caffa I., Soncini D., Costa-Fraga F.P., De Sousa F.B., Sinisterra R.D., Capettini L.A., et al. Treatment with angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. Thromb. Haemost. 2014, 111(4):736-747.
19. Fraga-Silva R.A., Ferreira A.J., Dos Santos R.A. Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension. Curr. Hypertens. Rep. 2013, 15(1):31-38.
20. Zulli A., Burrell L.M., Widdop R.E., Black M.J., Buxton B.F., Hare D.L. Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques. J. Histochem. Cytochem. 2006, 54(2):147-150.
21. Sluimer J.C., Gasc J.M., Hamming I., van Goor H., Michaud A., van den Akker L.H., Jutten B., Cleutjens J., Bijnens A.P., Corvol P., et al. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J. Pathol. 2008, 215(3):273-279.
22. Dong B., Zhang C., Feng J.B., Zhao Y.X., Li S.Y., Yang Y.P., Dong Q.L., Deng B.P., Zhu L., Yu Q.T., et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28(7):1270-1276.
23. Sahara M., Ikutomi M., Morita T., Minami Y., Nakajima T., Hirata Y., Nagai R., Sata M. Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation. Cardiovasc. Res. 2014, 101(2):236-246.
24. Thomas M.C., Pickering R.J., Tsorotes D., Koitka A., Sheehy K., Bernardi S., Toffoli B., Nguyen-Huu T.P., Head G.A., Fu Y., et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ. Res. 2010, 107(7):888-897.
25. Thatcher S.E., Zhang X., Howatt D.A., Lu H., Gurley S.B., Daugherty A., Cassis L.A. Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31(4):758-765.
26. Kulemina L.V., Ostrov D.A. Prediction of off-target effects on angiotensin-converting enzyme 2. J. Biomol. Screen. 2011, 16(8):878-885.
27. Shenoy V., Gjymishka A., Jarajapu Y.P., Qi Y., Afzal A., Rigatto K., Ferreira A.J., Fraga-Silva R.A., Kearns P., Douglas J.Y., et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am. J. Respir. Crit. Care Med. 2013, 187(6):648-657.
28. Nencioni A., da Silva R.F., Fraga-Silva R.A., Steffens S., Fabre M., Bauer I., Caffa I., Magnone M., Sociali G., Quercioli A., et al. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. Thromb. Haemost. 2014, 111(2):308-322.
29. Olivon V.C., Fraga-Silva R.A., Segers D., Demougeot C., de Oliveira A.M., Savergnini S.S., Berthelot A., de Crom R., Krams R., Stergiopulos N., et al. Arginase inhibition prevents the low shear stress-induced development of vulnerable atherosclerotic plaques in ApoE-/- mice. Atherosclerosis 2013, 227(2):236-243.
30. Maganto-Garcia E., Tarrio M., Lichtman A.H., et al. Mouse models of atherosclerosis. Current protocols in immunology 2012, 11-23. (Chapter 15:Unit 15 24). J.E. Coligan (Ed.).
31. Montecucco F., Di Marzo V., da Silva R.F., Vuilleumier N., Capettini L., Lenglet S., Pagano S., Piscitelli F., Quintao S., Bertolotto M., et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur. Heart J. 2012, 33(7):846-856.
32. Lambert D.W., Yarski M., Warner F.J., Thornhill P., Parkin E.T., Smith A.I., Hooper N.M., Turner A.J. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem. 2005, 280(34):30113-30119.
33. Mendoza A., Lazartigues E. The compensatory renin-angiotensin system in the central regulation of arterial pressure: new avenues and new challenges. Ther. Adv. Cardiovasc. Dis. 2015, 9(4):201-208.
34. Ramkhelawon B., Vilar J., Rivas D., Mees B., de Crom R., Tedgui A., Lehoux S. Shear stress regulates angiotensin type 1 receptor expression in endothelial cells. Circ. Res. 2009, 105(9):869-875.
35. Cardellini M., Menghini R., Martelli E., Casagrande V., Marino A., Rizza S., Porzio O., Mauriello A., Solini A., Ippoliti A., et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 2009, 58(10):2396-2401.
36. Hernandez Prada J.A., Ferreira A.J., Katovich M.J., Shenoy V., Qi Y., Santos R.A., Castellano R.K., Lampkins A.J., Gubala V., Ostrov D.A., et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008, 51(5):1312-1317.
37. Fraga-Silva R.A., Sorg B.S., Wankhede M., Dedeugd C., Jun J.Y., Baker M.B., Li Y., Castellano R.K., Katovich M.J., Raizada M.K., et al. ACE2 activation promotes antithrombotic activity. Mol. Med. 2010, 16(5-6):210-215.
38. Ferreira A.J., Shenoy V., Qi Y., Fraga-Silva R.A., Santos R.A., Katovich M.J., Raizada M.K. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp. Physiol. 2011, 96(3):287-294.
39. Fraga-Silva R.A., Costa-Fraga F.P., Murca T.M., Moraes P.L., Martins Lima A., Lautner R.Q., Castro C.H., Soares C.M., Borges C.L., Nadu A.P., et al. Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension 2013, 61(6):1233-1238.
40. Peregrine A.S., Mamman M. Pharmacology of diminazene: a review. Acta Trop. 1993, 54(3-4):185-203.
41. Qi Y., Zhang J., Cole-Jeffrey C.T., Shenoy V., Espejo A., Hanna M., Song C., Pepine C.J., Katovich M.J., Raizada M.K. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension 2013, 62(4):746-752.
42. Mecca A.P., Regenhardt R.W., O'Connor T.E., Joseph J.P., Raizada M.K., Katovich M.J., Sumners C. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp. Physiol. 2011, 96(10):1084-1096.
43. Fraga-Silva R.A., Costa-Fraga F.P., Montecucco F., Sturny M., Faye Y., Mach F., Pelli G., Shenoy V., da Silva R.F., Raizada M.K., et al. Diminazene protects corpus cavernosum against hypercholesterolemia-induced injury. J. Sex. Med. 2015, 12(2):289-302.
44. Foureaux G., Nogueira J.C., Nogueira B.S., Fulgencio G.O., Menezes G.B., Fernandes S.O., Cardoso V.N., Fernandes R.S., Oliveira G.P., Franca J.R., et al. Antiglaucomatous effects of the activation of intrinsic angiotensin-converting enzyme 2. Invest. Ophthalmol. Vis. Sci. 2013, 54(6):4296-4306.
45. Thatcher S.E., Zhang X., Howatt D.A., Yiannikouris F., Gurley S.B., Ennis T., Curci J.A., Daugherty A., Cassis L.A. Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 2014, 34(12):2617-2623.
46. Zhang Y., Liu J., Luo J.Y., Tian X.Y., Cheang W.S., Xu J., Lau C.W., Wang L., Wong W.T., Wong C.M., et al. Upregulation of angiotensin (1-7)-mediated signaling preserves endothelial function through reducing oxidative stress in diabetes. Antioxid. Redox Signal. 2015, [Epub ahead of print].
47. Lovren F., Pan Y., Quan A., Teoh H., Wang G., Shukla P.C., Levitt K.S., Oudit G.Y., Al-Omran M., Stewart D.J., et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2008, 295(4):H1377-H1384.
48. Zhang Y.H., Zhang Y.H., Dong X.F., Hao Q.Q., Zhou X.M., Yu Q.T., Li S.Y., Chen X., Tengbeh A.F., Dong B., et al. ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response. Inflamm. Res. 2015, 64(3-4):253-260. (et al.).
49. Zhang K., Meng X., Li D., Yang J., Kong J., Hao P., Guo T., Zhang M., Zhang Y., Zhang C. Angiotensin(1-7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade. Kidney Int. 2015, 87(2):359-369.
50. Liu C.X., Hu Q., Wang Y., Zhang W., Ma Z.Y., Feng J.B., Wang R., Wang X.P., Dong B., Gao F., et al. Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. Mol. Med. 2011, 17(1-2):59-69.
51. Moreno P.R., Purushothaman M., Purushothaman K.R. Plaque neovascularization: defense mechanisms, betrayal, or a war in progress. Ann. N. Y. Acad. Sci. 2012, 1254:7-17.
52. Michel J.B., Martin-Ventura J.L., Nicoletti A., Ho-Tin-Noe B. Pathology of human plaque vulnerability: mechanisms and consequences of intraplaque haemorrhages. Atherosclerosis 2014, 234(2):311-319.
53. Velkoska E., Patel S.K., Griggs K., Pickering R.J., Tikellis C., Burrell L.M. Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy. PLoS One 2015, 10(3).